Archives: News

As the COVID-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health in Australia

Sydney, Australia. February 3, 2022 — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on March 8 as a day to recognise the growing health disparities women face that have been exacerbated by the COVID-19 pandemic¹. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and is starting with its own employees, including the almost 100 in Organon Australia, by providing paid time off this year for all employees to attend to their own health needs. The company invites organisations in Australia and across the globe to join in raising awareness of the inequity in women’s health and to adopt initiatives that help women prioritise their health.

Women have worked hard to advance in the workplace, but the pandemic is unraveling these hard-fought gains. Many women are now significantly more burned out than ever, even more than men¹ — which can take a huge toll on their physical and mental health. The Jean Hailes’ Women’s Health Survey 2020 Snapshot reports that 31.7% of women aged 25 – 44 did not have enough time to attend health check appointments, and one in four could not get an appointment when they needed one².

“Organon launched with a commitment to listen to the needs of women and as part of our research, we learned that women are finding it harder than ever to make the time to care for even their most basic health needs,” said Kevin Ali, chief executive officer, Organon. “As a company investing in innovation to improve women’s health, I felt a responsibility to help address this within our own global community of almost 9,500 employees. This year, the symbolic action we are taking is to encourage all our people to spend this day off to make a commitment to their own health or the health of the women in their lives, whether that’s going to the doctor, taking stock of their own wellbeing or reflecting on how to make a change.”

“We believe healthy women are the backbone of a thriving, stable and resilient society and when she is healthy, she prospers and so does her community, her society for generations to come. The Australian Federal Government’s National Women’s Health Strategy 2020 – 2030³ recognises the gaps in health outcomes and key health inequities exists for women and girls, and seeks to address these”, said Nirelle Tolstoshev, managing director for Organon Australia.

An online survey of 10,000 Australian women conducted between February and April 2021 by Australia’s National Research Organisation for Women’s Safety, found that COVID has had an impact on women’s personal and professional lives, as well as that of her family⁴.

One in three women (31 per cent) in the survey had been laid off, lost their job or had to take a pay cut or reduce hours, in the first 12 months of the pandemic. As a result, women reported being unable to pay bills on time, needing to pawn or sell something, going without needed medical or dental treatment, and skipping meals. This has a profound impact not only on women, but also their families and their communities.

This is what Organon is hoping to change, and we are asking others to join in the effort to improve women’s health.

“We foster a People First culture to support our people, our customers and the communities in which we live and work. Empowering women to put their health needs at the top of the priority list is part of the change we need to drive to increase gender equity in all aspects of their lives,” continued Tolstoshev.  “Especially as the pandemic continues to limit women’s ability to take care of themselves, we are proud to show our commitment to meeting women’s unmet health needs today and into the future.”

We believe that by improving the understanding of women’s health needs, we are one step closer to closing the inequity gap. Organon urges all organisations to join in this mission and be part of the solution. Visit hereforherhealth.com/make-time to learn more.

About Organon

Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Copyright © (2022) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113.

AU-NON-110002. First issued February 2022.

To learn more about Organon, please visit https://organon.com/australia/

REFERENCES:

Organon now the only healthcare company to have dual membership of MA and GBMA

Just five months after our launch in June 2021, Organon has become members of both Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA), and is the only healthcare company in Australia to be members of both industry representative organisations.

“Organon Australia is proud to be members of both Medicines Australia as well as Generic and Biosimilar Medicines Association.  Our commitment is to the health and wellbeing of women, and we look forward to using our voice to advocate for access and innovative treatments to support a healthier every day for every woman,” said Luke Cornish, Access and External Affairs director.

“This is a very important time for the pharmaceutical industry, with Australians recognising the value that medicines and our industry brings. Our clear and dedicated focus on the health of women is at the centre of everything we do, and membership of both MA and GBMA means that we can focus on making a positive contribution toward a healthcare environment which offers patient’s choice, and supports innovation and access in medicines by helping to manage the healthcare budget.”

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

Copyright © (2021) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.

Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace.

Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace.  Family Friendly Workplaces is a joint initiative of Parents at Work and UNICEF Australia, and measures workplaces against standards developed to encourage employers to benchmark their own internal policies against nationally recognised best practices.

One of our priorities when we formed was to give our Founders a voice through employee resource groups (ERGs).  The Families@Work ERG were keen to benchmark how Organon was positioned in living up to its commitment to people first, as well as to explore opportunities to consistently aim for ongoing improvement.

Tim Cogin, Director Fertility, Organon ANZ, is the sponsor for the Families@Work ERG, commented, “We are incredibly proud that we have been able to achieve certification as a Family Friendly Workplace in our first four months since establishing as a company.  We are in unique times of high stress, and never before has work and family life been so closely integrated. We always want our people to feel good about balancing their work priorities with their family priorities. We know that family comes first, and it is important that workplaces reflect this and adapt accordingly.”

Organon recognises the need to support families in all their forms and has policies to bring this to life for every employee. Initiatives such as the Gift of Time which allowed time off for parents who home-schooled children during the COVID lockdowns and encouraged all employees to take time during the workday to focus on their own health and wellbeing; Focus Fridays which discourages meetings on Fridays and enables a 3pm finish, so that our Founders can focus on deep thinking and completing work without the pressure of meetings; and a unique Principles-based Work @ Organon approach to office attendance are demonstrations of our recognition  that families come in all shapes and sizes and vary depending on life stages.  We also have plans to continue to evolve our offering over time, and with input from our Founders.

Sophie Althans, Director HR with Organon ANZ shares her perspective on the impact of supporting Founders in all their unique requirements.  “I’m proud of the unique people first culture that we actively foster in every decision we make.  Embracing flexibility and being open with how our teams work and evolve has a significant correlation with our strong employee engagement across a range of measures. We continue to foster an agile environment in which all Founders have a sense of belonging and bring their valuable diverse perspectives in wholeheartedly embracing Organon’s values.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Growing a business with a commitment to listen to women to understand her health needs requires different thinking and approaches

Just four months since its launch as the only global company of its size focused on women’s health, Organon in Australia continues to invest in people to deliver on its focus on women’s health through its portfolios of women’s contraception and fertility, biosimilars and established brands.

One unique approach has been to attract people from outside of the traditional pharma sector for fresh eyes and fresh ideas.  In just four short months, Organon has grown its employee founder base with six senior positions filled from diverse industries including the construction, FMCG, Medical Devices, automotive and political sectors.

“We have brought in external people that are non-pharma, and already we’re seeing new perspectives, new reference points and new approaches – opening our lateral and strategic thinking. We embrace the different insights and energy and we’re saying don’t wait to settle in, we want to hear your ideas now,” said Nirelle Tolstoshev, Managing Director, Organon ANZ.

Attracting the best people to support Organon’s strategy to lead and evolve as a progressive, future fit and dynamic organisation is proving to be a successful part of Organon’s success, including two additions to the Organon Leadership Team, with Sophie Althans commencing as HR Director and Mark Coleman taking the role of Strategy and Organisational Development Lead.

Sophie is a member of both the ANZ Leadership Team and the Regional HR Leadership Team.  She will oversee the continuing development of Organon ANZ’s people and culture of engagement to support short term business execution and long-term transformation. Sophie has a wealth of experience in supporting organisations to achieve their business priorities through driving effective talent strategies. As well as expertise in the pharmaceutical sector, Sophie has also worked in Medical Devices, Supply Chain and FMCG.

Mark Coleman joins in a novel role specifically designed to lead Organon’s organisational development strategy.  Mark has over 20 years’ experience in healthcare, and is passionate about helping teams thrive through creating environments that enable learning, reflection and growth.

In an early indication of the commitment to a culture of people first, entrepreneurship, and a mindset focused on future requirements, Mark will support the organisation to realise the company vision and values.

“With their deep expertise in people, processes to foster learning, business excellence, and continuous improvement for growth, I am confident that Sophie and Mark will make great contributions to our business,” said Nirelle Tolstoshev.

Organon in Australia is one of the few markets globally to have all three core pillars of Women’s Health, Biosimilars and Established Brands.

To learn more about Organon, please visit Home | Organon or Organon ANZ on LinkedIn

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Building on vision to create a better and healthier every day for every woman, Organon launches video to challenge and help reduce stigma of global public health issue

SYDNEY – Organon (NYSE: OGN), a global women’s health company, is hoping to address the staggering rates of unplanned pregnancies around the world by launching a video to raise awareness and ignite a worldwide conversation around unplanned pregnancy.

Worldwide modelling estimates that unplanned pregnancy impacts approximately 121 million women each year.¹ A 2019 study reported that globally, more than 1 billion women have a need for family planning, but for 270 million of them, that need for modern methods is unmet.^2** Unplanned pregnancy can impact any woman anywhere – regardless of her social or economic background.

In Australia, one in four women had an unintended pregnancy in the past 10 years, and 30 per cent of unintended pregnancies ended in abortion.³ The rates are even higher in rural and remote locations, with women in rural areas are 1.4 times more likely to experience an unintended pregnancy.⁴  For younger people aged 18-32 years, 40.8 per cent reported an unintended first pregnancy.⁴

“While we have seen a lot of progress in the area of reproductive health, the rates of unplanned pregnancy continue to be high,” said Margie Austin, Women’s Health Business Director for

__________________________________

¹ Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6

² Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards meeting women’s contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med 17(2): e1003026. https://doi.org/10.1371/journal.pmed.1003026

³ Taft et al (2018). Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes. Med J Aust, 209 (9): 407-408

⁴ Rowe et al. (2015). Prevalence and distribution of unintended pregnancy: the Understanding Fertility Management in Australia National Survey. ANZJPH, 40(2):104-9.

**According to Kantorová et. al, modern methods of contraception include female and male sterilization, the intrauterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the lactational amenorrhea method (LAM), emergency contraception and other modern methods such as the contraceptive patch or vaginal ring.

Organon Australia. “There is no better time than ahead of World Contraception Day to focus on empowering her through education, information, empathy and conversation to help reduce unplanned pregnancy.

General Practitioner with a special interest in women’s health, including contraception and menopause, Dr Meredith Frearson believes that contraception enables women to plan their path. “Today’s contraceptive options are wide and varied and I encourage all women to take the time to discuss their options with their health care providers.  Even in Australia many women may not be aware of the increasing range of options open to them and the additional benefits that some contraceptives can provide such as reducing menstrual loss and pain and assisting with changing needs as she reaches menopause.

“Contraceptive choices may well change across a woman’s reproductive lifespan. The introduction of several longer lasting methods has made a huge difference for many women who find having a reliable set and forget method to be a major bonus. I encourage women to embrace change and take the time to find out about their options from reliable sources,” Dr Frearson said.

“There is still so much we can do across our global and local communities to help raise awareness about unplanned pregnancy and work collectively towards lowering the rates,” Austin continued. “Today marks the beginning of a new conversation, one that is geared towards reducing the stigma of unplanned pregnancy and giving her the information she needs to make informed decisions.”

Organon invites women, their families, healthcare professionals, and policy makers to visit HereforHerHealth.com to share their perspectives on how to help reduce the rates of unplanned pregnancy and join us on a collective mission of having the conversation.

The video is available on HereforHerHealth.com where people are encouraged to share their perspective on how to help reduce unplanned pregnancy.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Women’s healthcare company Organon kicks off its global Organon Wellness Month in August, and the Australian subsidiary is making the most of the opportunity with a comprehensive program to promote employee health and wellbeing.

The month-long program aims to increase awareness and facilitate employee engagement focused on four pillars of wellness: physical; mental; professional; and social.

Based on these four pillars, Organon will reward employees who participate in the various programs offered, which include personalised health and wellness assessments; increase their daily physical activities; practice meditation techniques; or making time to develop and share hobbies.  Reward incentives to further prompt employee engagement include fitness and massage vouchers. This initiative is complimented with a previously established $250 Wellness Reimbursement Program which can be used to pay for a wide range of wellbeing programs and equipment.

With COVID-19 impacting the work, home and school environment, Organon has increased its focus on workplace flexibility and initiatives to foster a more sustainable working environment which includes encouraging all employees to take time during the workday to focus on their health as well as that of their family and community.

“Through this commitment and various initiatives that our people can choose from, we recognise and respect the diversity of each person’s needs. We believe that our employees will emerge from this period feeling more energised and with some fuel in the tank, versus being totally exhausted with no annual leave left. We just think that this is a more sustainable approach, ” said Nirelle Tolstoshev, managing director Organon ANZ.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

Copyright © (2021) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.